Clinical observation of Oxaliplatin plus S-1 or Gemcitabine as first-line therap
PUBLISHED: 2015-11-27  351 total views, 1 today

Cheng Zhou, Xiaofeng Chen, Yongmei Yin

Department of Medical Oncology, Jiangsu Provincal Hospital


Objective:To observe the clinical efficacy and adverse reactions of oxaliplatin combined with S-1 or gemcitabine as first-line chemotherapy for patients with biliary tract cancer. Method: A retrospective analysis of the advanced biliary tract cancer patients treated in our department from July 2009 to July 2014 was performed. According to the inclusion criteria, there were 57 patients who treated with oxaliplatin combined with S-1 (SOX) regimen or oxaliplatin combined with gemcitabine (GEMOX) regimen as the first-line chemotherapy. Collected and analyzed their age, sex, primary tumor site, metastasis site, et al. The following data were analyzed: rate of response (RR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse reactions of the two groups of patients. Result:In the 30 patients of Sox group: 0 cases of complete response (CR),5 cases of partial response (PR),13 cases of stable disease (SD),12 cases of progressive disease (PD), the rate of response (RR) was 16.7%,disease control rat (DCR) was 60.0%, median progression free survival (mPFS) was 6.94 months, median overall survival (mOS) was 12.01 months; In the 27 patients of GEMOX regimen group: 1 patients of CR, 8 cases of PR,10 cases of SD,8 cases of PD,RR was33.3%, DCR was 70.3%, mPFS was 6.85 month, mOS for 12.21 months. Adverse reactions mainly included I~II degree of leucopenia, anemia, thrombocytopenia, nausea/ vomiting, et al. No patient discontinued owing to adverse events, no chemotherapy related deaths. Conclusion: Sox and GEMOX regimen are both effective and well tolerated in advanced biliary tract cancer patients as the first-line chemotherapy. However, due to the wide range of time periods and the small sample size of this study, the results should be interpreted with caution, further studies are required.


Key Words: biliary tract cancer  first line therapy  clinical

Copyright © 1998 - 2019 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)